Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Randomized, Double-blind, Placebo-controlled, Multi-site, Proof of Concept Trial to Evaluate the Efficacy and Safety of LEO 138559 in Adult Subjects With Moderate to Severe Atopic Dermatitis (AD).

NCT04922021 is registered in ClinicalTrials.gov with LEO Pharma as lead sponsor.

NCT NCT04922021
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04922021 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Randomized, Double-blind, Placebo-controlled, Multi-site, Proof of Concept Trial to Evaluate the Efficacy and Safety of LEO 138559 in Adult Subjects With Moderate to Severe Atopic Dermatitis (AD).
Lead sponsor
LEO Pharma
Phase
Phase 2
Overall status
Completed
Start date
July 14, 2021
Completion date
September 26, 2022
Enrollment
58 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis